About TACT

TACT is a unique opportunity to improve outcomes for patients with thoracic malignancy by facilitating clinical research through a truly global network, harmonisation of governance and operations and fostering a genuine collaboration among groups and with external partners.

TACT was established in September 2015 as an international non-profit umbrella organisation for academic groups worldwide, dedicated to thoracic oncology research. TACT is led by a Board comprising representatives of key national and trans-national cooperative thoracic oncology groups. Secretariat support is provided by Lung Foundation Australia (LFA), the legal entity incorporated in Australia* under which TACT was established.

 

Download a presentation about TACT (opens in a new tab)

 

TACT aims to:

 

  • Facilitate and promote international research collaboration in thoracic cancer
  • Provide a platform to conduct clinical trials requiring multiple trials groups
  • Combine resources and expertise to conduct research more efficiently and reduce duplication of effort
  • Allow trials to recruit more quickly
  • Establish clinical and translational research priorities

 

TACT will:

 

  • Develop and conduct trials which require large numbers of patients and/or where accrual is difficult, such as  multi-modality therapy and rare thoracic malignancies or subtypes
  • Conduct translational research
  • Collaborate with other scientific networks
  • Develop models of collaboration with the pharmaceutical and biotechnology industry that preserve scientific independence
  • Promote other academic thoracic oncology activities

 

*LFA is a not-for-profit company limited by guarantee that is registered as a charity in Australia and has been granted Deductible Gift Recipient (DGR) status.